ArticleCureus2025

Weekly Versus Three-Weekly Administration of Paclitaxel as Neoadjuvant Chemotherapy in HER2 Negative, Stage III Breast Cancer: A Comparison of Treatment Responses.

Shourov Biswas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.